Rimonabant (Acomplia) - Weight Loss Pill

Rimonanbant, also commonly known as Acomplia, is a diet pill. It is an anti-obesity medication that functions by decreasing the appetite. It is a selective CB1 receptor blocker, as well as an inverse agonist for cannabinoid receptor type 1. This weight loss pill is not available in North America, but in Europe and several outside nations (it is available in 56 countries in total). It is intended to be taken alongside a well-balanced, low calorie diet and a regular exercise regimen.

Rimonabant Acomplia is supposed to used for individuals suffering from obesity. Users of this diet pill must have a body mass index (BMI) that is higher than 27. They also must be at high risk for developing medical conditions that are directly linked to obesity, such as type 2 diabetes and dyslipidemia (which is a lipoprotein metabolism disorder).

Rimonabant is supposed to help individuals with losing weight. However, there are several other benefits that are commonly associated with the weight loss pill. These include helping people with quitting smoking, and weight-related benefits, such as changing the HDL (high-density lipoprotein) "good" cholesterol, triglyceride and CRP (C-reactive protein) levels of its users.

Extreme depression is considered to be a common, unpleasant side effect of the weight loss pill. This is believed to be due to the fact that the pill is highly active in its users' central nervous systems.

It is also believed that, as a side effect of the pill, Rimonabant encourages the occurrence of neurodegenerative diseases relating to the central nervous system, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and Huntington's disease. As a result, individuals living with any neurological disorders are strongly urged against taking Rimonabant

Rimonabant is available in many different European countries. It is available as a non-prescription weight loss pill in the United Kingdom. It is also available in nations such as Ireland, Belgium, Germany, Norway, Sweden, Denmark and Finland. It does not have approval from the United States Food and Drug Administration (FDA), and is not available in the USA.